> Retour à la liste des séminaires

Séminaire

Mercredi 18 Juillet 2018
16h
Centre de Recherche - Paris - Amphithéâtre Antoine Lacassagne

Nanostring: Bringing the next generation Biomarkers to the clinic

Current research tools to predict patient response to immunotherapy are hampered by low information content, limited reproducibility, high input requirements, cumbersome protocols, or slow turn-around time. Dr Cesano will describe multiplexed assay designed to triage patients to novel and existing immunotherapies and combinations based on the parallel assessment and integration, in one single assay and sample, of multiple mechanisms of immune evasion.
In addition, Dr Cesano will present NanoString’s Digital Spatial Profiling technology (DSP). The DSP technology performs a whole slide imaging, allowing in one single reaction, to capture tissue morphology and to select regions of interests for highly multiplexed, spatially resolved profiling experiments with up to 800 barcoded reagents
.

Orateur(s)

Alessandra Cesano
Chief Medical Officer

Nanostring Technologies HQ

Invité(e)(s) par

Emanuela Romano

Institut Curie

Contact

Sylvia Trival

Lui envoyer un mail

En bref

Alessandra Cesano, M.D., Ph.D. is the Chief Medical Officer of nanoString Inc since July 2015. Prior to joining nanoString, Dr. Cesano was Chief Medical Officer at Cleave Biosciences, Inc. From 2008 to 2014, she served as Chief Medical Officer and Chief Operations Officer at Nodality, Inc., where she built and led the R&D groups, while providing the overall clinical vision for the organization. In addition, Dr. Cesano has held various management positions at Amgen, Biogen Idec and SmithKline Beecham Pharmaceuticals, where she helped to advance various oncology drugs through late stage development and FDA approvals. Dr. Cesano spent 12 years researching tumor immunology, including nine years at the Wistar Institute, an NCI Basic Cancer Center at the University of Pennsylvania. She also holds membership in several professional and scientific societies, and has been an author on over 100 research publications. Dr. Cesano received an M.D., a Board Certification in Oncology and a Ph.D. in Tumor Immunology from the University of Turin. She holds a B.S. in Science and Economics from Istituto Tecnico Commerciale.l@